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ABSTRACT  
Background: Immunization is an important public health intervention for vaccine-
preventable diseases (VPDs). However, adverse events may follow immunization of 
infants. This study determined the prevalence and management of Adverse Events 
following Immunization (AEFI) reported by caregivers of infants in Well-Baby Clinics in 
Benin City, Nigeria. 
Methods: The study was carried out in 2015 among 400 caregivers of infants attending 
Well- Baby Clinics in Benin City, Nigeria. A descriptive cross-sectional study design was 
utilized. Respondents were selected using a systematic sampling technique. An adapted 
structured interviewer-administered questionnaire was used to collect data. Data 
analysis was done using IBM SPSS version 20.0. 
Results: Less than half, 169 (42.3%) of the caregivers stated that their children had AEFI. 
Three-quarters 126 (74.6%) and 68 (40.2%) of the AEFI occurred following vaccination 
with Bacillus Calmette-Guerin and pentavalent vaccine. Fever and swelling of the 
injection sites occurred in 142 (84.0%) and 65 (38.5%) of the children, respectively. 
Almost all 167 (98.8%) of the respondents reported an AEFI.  Few of those who reported 
an AEFI, 13 (7.8%) had their children hospitalized. 
Conclusion: A significant proportion of children vaccinated experienced side effects 
perceived to be AEFI that presented mainly as fever and swollen injection sites which 
were mainly reported at the immunization clinic. Few of the reported cases of AEFI were 
hospitalized. Healthcare workers should continue to educate and reassure caregivers of 
infants of the symptoms and signs that may occur following vaccination and how they 
can be managed.  
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Immunization remains one of the most 
important public health interventions and a 
cost-effective strategy to reduce both the 
morbidity and mortality associated with 
vaccine-preventable diseases (VPDs).1 
Immunization is essential in achieving 
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targets 3.3 and 3.8 of the Sustainable 
Development Goals (SDG) which hope to 
end epidemics of communicable diseases 
and achieve universal health coverage by 
2030, respectively.2,3 According to the 
International Vaccine Access Center (IVAC) 
projections, achieving immunization 
coverage of 90% in Nigeria in the next 
decade will increase the country’s economy 
by $17 billion.4 Despite the numerous 
benefits of immunization, uptake of 
vaccines is still very low especially in 
developing countries making VPDs the most 
common cause of childhood mortality with 
an estimated 2-3million deaths each year.3 
Reasons for low immunization coverage 
have been linked to health system-related 
and family/caregivers factors. The health 
system-related factors are: lack of proper 
planning, issues with services delivery, 
decreased motivation of health workers, 
failure to access immunization status of 
children during visits to health facilities; 
while the family/caregivers factors include: 
lack of awareness, lack of time and other 
family issues, plus issues of mistrust and 
fear of adverse effects following 
immunization (AEFI).5 Although the 
immunization coverage in Nigeria for the 
last ten years has improved, it fell short of 
the Millennium Development Goals (MDG) 4 
target of 90% by 2015.6 According to the 
Multiple Indicator Cluster Survey in 2017, 
full immunization coverage stood at 53 in 
1000 for Nigerian children with 9% of 
women refusing to get their children 
vaccinated due to the fear of side effects.7  
AEFI can be categorized as follows: vaccine 
product-related reactions due to one or 
more of the inherent properties of the 
vaccine product; vaccine quality defect-
related reactions due to one or more quality 
defects of the vaccine product including its 
administration device as provided by the 
manufacturer. Others include immunization 
error-related reactions which occur when 
there is inappropriate vaccine handling, 
prescribing and administration; immunization 
anxiety-related reaction which arises from 
anxiety about the immunization; and 
coincidental events which are due to other 
factors apart from those listed above.8 
Common AEFI include pain, swelling or 
redness at the site of injection, local 
abscess, fever, malaise and myalgia.9 Severe 
allergic reactions and encephalitis following 
immunization are often rare. The number of 
reported cases of AEFI increases during 
immunization campaigns. Between 2013 
and the first quarter of 2018, a total of 
12,637 cases of AEFI were reported with 72 
classified as serious from measles, yellow 
fever and meningitis campaigns conducted 
in Nigeria. Investigation and causality 
assessment showed that the majority were 
coincidental.10 Efforts have been made to 
strengthen the AEFI surveillance system in 
Nigeria by the Federal Government through 
the support of the World Health 
Organization (WHO). For instance, the AEFI 
National Expert Committee was 
inaugurated with the responsibility of 
ensuring that Nigerian health workers will 
be able to monitor and prevent AEFI.10 
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A study conducted in Ilorin, Nigeria, showed 
that 50.9% of documented cases of AEFI 
reported were local swelling at the injection 
site, followed by cellulitis (29.8%). About 
half, 49.1% of the reported AEFI cases 
occurred after administering Diphtheria, 
Pertussis and Tetanus (DPT).11 Another 
study conducted in Enugu among 331 
mothers revealed that 190 (57.4%) of the 
respondents managed AEFI by giving 
paracetamol, 43 (19.5%) took their children 
to the hospital, while 2 (0.9%) used herbal 
mixtures.12 AEFI affects immunization 
uptake. Hence, it is important to find out the 
prevailing pattern of occurrence and 
management of AEFI in the study locale in 
order to influence evidence-based policy 
decision-making and planning for 
immunization services. This study tried to 
determine the prevalence and management 
of perceived AEFI in infants attending Well-
Baby Clinics in University of Benin 
(UNIBEN) and University of Benin Teaching 
Hospital (UBTH), Benin City. 
METHODOLOGY 
The study was carried out in two well-baby 
clinics: The National Programme on 
Immunization (NPI) Clinic, Public Health 
Department, UBTH and the Nutrition, 
Education and Rehabilitation Unit, Institute 
of Child Health, UNIBEN, both in Benin 
City, Nigeria. The NPI Clinic is located in the 
service area of the General Practice Clinic 
(GPC), UBTH. The clinic carries out children 
immunization every day of the week except 
during the weekends. Approximately 200 
children are immunized daily. The 
Nutrition, Education and Rehabilitation 
Unit of the Institute of Child Health, 
University of Benin Clinic is located in Oba 
Akenzua Building Complex in UBTH. It 
carries out immunizations on Mondays, 
Wednesdays and Fridays. About 20 children 
are immunized daily at the clinic. A 
descriptive cross-sectional study design was 
utilized. Caregivers who brought their 
infants for immunization at the Well Baby 
Clinics were the respondents for the study. 
All caregivers whose infant had received 
immunization at the clinics at least once 
were recruited. This was to ensure that the 
respondents’ children had previously been 
exposed to vaccines with possible AEFI 
experience. The sample size was calculated 
using Cochran’s formula for descriptive 
studies.13 A prevalence rate of 34.9% from a 
study conducted in Kano, Nigeria was used 
in calculating the minimum sample size of 
349.14 However, 400 respondents were 
utilized for the study after adding 10% non-
response rate.   
The respondents were selected using 
systematic sampling technique. The study 
centres had an average daily attendance of 
220 caregivers. Data collection was 
scheduled for 10 working days with a target 
of 40 respondents daily. After calculating 
the sampling interval of 6, simple random 
sampling through balloting was used to 
select the first sample from the sampling 
frame. Subsequently, every 6th client on the 
clinic attendance list was selected using 
proportional allocation of sample population 
for the two clinics. The tool for data 
collection was a pretested, structured, 
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interviewer-administered questionnaire. 
The data collected were screened for 
completeness and analyzed using IBM SPSS 
version 20.0 software. Results were 
presented using prose, simple frequency 
and cross tables. Test of association was 
done using Chi-square test and p < 0.05 was 
taken to be statistically significant. Ethical 
approval for this study was obtained from 
the Ethics and Research Committee in 
UBTH. Institutional approval was also 
obtained from UBTH and UNIBEN 
managements. In addition, verbal informed 
consent was also obtained from the 
caregivers after they were educated on the 
purpose, benefits and the minimal risks of 
the study before the questionnaire was 
administered. 
RESULTS 
The mean (Standard deviation) age of the 
caregivers was 29.1 (4.6) years. A majority 
of the caregivers 367 (91.8%) had at least, 
secondary level of education. Almost half of 
the children, 194 (48.5%) were less than 3 
months old while 69 (17.3%) were more than 
6 months old. Males made up 249 (62.3%) 
of the infants. Over half, 216 (54.0%) of the 
children were of 1st and 2nd birth order. 
Three-quarters, 303 (75.8%) had three or 
less siblings. (Table 1) In Table 2, less than 
half, 169 (42.3%) of caregivers stated that 
their children had a previous AEFI. Fever 
was the commonest AEFI reported by 
majority, 142 (84.0%) of the caregivers, 
followed by swelling and pain at the 
injection site. Majority of the respondents 
claimed that the AEFI occurred 24 hours or 
more after the vaccine was administered 
106 (62.7%) and especially after the first 
dose of vaccine was given 107 (63.3%). 
Three-quarters of the caregivers, 126 
(74.6%) reported a previous AEFI episode 
following BCG vaccination, while 68 
(40.2%), 48 (28.4%) and 40 (23.7%) stated 
that the AEFI occurred following 
pentavalent, measles and yellow fever 
vaccine respectively. 
The occurrence of AEFI increased with the 
age of the infants and was experienced more 
by parents with not more than 4 children. 
Also, the occurrence of AEFI was more 
among infants within the 3rd and 4th birth 
order.  The occurrence of AEFI was 
significantly associated with infants’ age (p< 
0.001), parent’s number of children 
(p=0.018) and child’s birth order (p< 0.001). 
(Table 3) Among the 169 caregivers whose 
children have had AEFI, 167 (98.8%) of 
them had reported the occurrence. Most, 
136 (81.4%) reported at the immunization 
clinics, mainly to the nurses 158 (94.6%). 
Majority of the respondents, 97 (58.1%) 
reported a few hours after the onset of the 
AEFI. The major management information 
given during health education session on 
AEFI was that the infant should be taken to 
the hospital. Other management options 
mentioned included: use of paracetamol 
tepid sponging. Only 13 (7.8%) of the infants 
reported to have had AEFI were 
hospitalized. Fever was the major cause of 
hospitalization as a result of AEFI 7 (53.8%). 
Other symptoms for hospitalization are skin 
reactions and swelling of the vaccination 
site. Table 4. 
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Table 1: Socio-demographic characteristics of the caregivers’ and infants 
Characteristics Frequency (n=400) Percent 
Age of caregivers (years)   
19 – 24 33 8.2 
25 – 30   267 66.8 
31 – 35 78 19.5 
36 – 40  16 4.0 
≥ 41 6 1.5 
Marital Status of caregivers  
Single 7 1.8 
Married 393 98.2 
Level of Education of caregivers   
No formal education 7 1.8 
Primary 26 6.4 
Secondary 231 57.8 
Tertiary 136 34.0 
Occupation of caregivers   
Unemployed 102 25.5 
Skilled level I 169 42.3 
Skilled level 2 67 16.8 
Skilled level 3 4 1.0 
Skilled level 4 58 14.7 
Age of  infants (months)   
< 3  194 48.5 
3 – 6  137 34.3 
> 6  69 17.2 
Sex of infants   
Male 249 62.3 
Female 151 37.7 
Birth order of infants   
1st 122 30.5 
2nd 94 23.5 
3rd 72 18.0 
4th 15 3.8 
≥ 5th 97 24.2 
Number of children by parents   
≤ 4 303 75.8 
> 4 97 24.2 
Mean age (caregivers) = 29.1±4.6 years  




The prevalence of AEFI in this study was 
42.0%. This is higher than the 34.9% 
reported in a similar study carried out in 
Kano, Nigeria.14 A possible explanation for 
this is the difference in the educational 
status of caregivers observed in both studies 
where 34.1% of the respondents in this 
study had tertiary education as against 
12.4% in the Kano study.  Educated 
mothers will likely have better 
understanding of possible side effects of 
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Table 2: Perceived AEFI experienced by respondents’ children 
Variable Frequency  Percent   
Child ever had AEFI (n=400) 
Yes 169 42.3 
No 231 57.7 
Type of AEFI experienced* (n=169) 
Fever 142 84.0 
Swelling at injection site  65 38.5 
Pain at injection site  62 36.7 
Cough 42 24.9 
Duration after vaccination for the occurrence of AEFI (n=169) 
Immediately after vaccination 1 0.6 
1 – 23 hours 62 36.7 
≥ 24 hours 106 62.7 
Vaccine dose at which AEFI occurred (n=169) 
First  107 63.3 
Second  62 36.7 
Vaccine followed by AEFI* (n=169) 
Bacillus Calmette Guerin (BCG) 126 74.6 
Pentavalent vaccine 68 40.2 
Measles vaccine 48 28.4 
Yellow fever vaccine 40 23.7 




Table 3: Children’s socio-demographic variables and the prevalence of AEFI  
                  Ever had an AEFI 
     









Age of child (months) 
< 3  45 (23.2) 149 (76.8) 62.454 < 0.001* 
3 – 6 74 (54.0) 63 (46.0)  
> 6 50 (72.5) 19 (27.5)  
Sex of child  
Male 102 (41.0) 147 (59.0) 0.447 0.504 
Female 67 (44.4) 84 (55.6)  
Number of children by parents  
≤ 4 138 (45.5) 165 (54.5) 5.558 0.018* 
> 4 31 (32.0) 66 (68.0)  
Birth    
order 
1 – 2 72 (33.3) 144 (66.7) 51.533 < 0.001* 
3 – 4 66 (75.9) 21 (24.1)  
≥ 5 31 (32.0) 66 (68.0)  
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Table 4: AEFI reporting and management protocol among respondents 
Variable Frequency  Percent   
Ever reported any AEFI (n = 169) 
Yes 167 98.8 
No 2 1.2 
 
Place of reporting (n=167) 
Immunization clinic 136 81.4 
Patent Medical Store 31 18.3 
 
Health personnel reported to (n=167) 
Doctor 9 5.4 
Nurse 158 94.6 
 
Documentation of the report (n=167) 
Yes 55 32.9 
No 12 7.2 
Do not know 100 59.9 
 
Period of reporting AEFI (n=167) 
Immediately 14 8.4 
When symptoms worsened 56 33.5 
Few hours after onset 97 58.1 
 
Management protocol mentioned at health education session*  
Come to the hospital 140 83.8 
See your doctor 74 44.3 
Give paracetamol 31 18.6 
Tepid sponging 26 15.6 
Do not press site 10 6.0 
Cannot recall 5 3.0 
aHospitalization of respondents children because of AEFI (n=167) 
Yes  13 7.8 
No 154 92.2 
 
Cause for hospitalization (n=13) 
Fever 7 53.8 
skin reactions 4 30.8 
Swelling 2 15.4 
*Multiple responses  
a All the respondents also stated that their children fully recovered after treatment 
 
 
The prevalence of AEFI was higher in 
children who were more than 6 months old. 
This was in contrast to findings in a study 
conducted in Ilorin Nigeria, where AEFI was 
more in children 2-4 months old.11 A 
possible reason for this may be because this 
age group has been exposed to more 
vaccinations, and have a higher chance of 
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experiencing adverse effect than children 
who are younger and have received fewer 
vaccines.  
The commonest AEFI reported was fever, 
followed by pain and swelling at the site of 
administration of the vaccines. Similar 
findings were documented in other studies 
done in Nigeria.15,16 BCG and Pentavalent 
vaccines were the most commonly reported 
causes of AEFI. This corresponds to the 
findings in a record based descriptive study 
done in Brazil which reported that  BCG 
vaccine was responsible for 41.3% of all 
cases of cold subcutaneous abscess, 
lymphadenitis and ulcers bigger than 
1cm.17 The findings also tallied with results 
from a study done in Ilorin, Nigeria where 
DPT was the most commonly reported cause 
of AEFI.11 This might, however, be due to 
difference in timing of administration of the 
vaccines as caregivers tend to remember 
events that are closer to the birth of the 
child. Majority of the AEFI occurred more 
than 24 hours after vaccination, a finding 
similar to what was observed in a study 
conducted in China.18 This may support 
evidence that the adverse events were due to 
vaccination and not coincidental. The 
majority of the respondents showed that the 
AFEI occurred after the first dose of the 
vaccines. A similar finding was reported in a 
study done in Iran which revealed that most 
AEFI were more frequently observed after 
the first dose than the second dose of 
vaccination with the pentavalent vaccine.19 
This may be because the immune system is 
already sensitized after the first dose leading 
to better tolerance upon administration of 
the second dose. There was no obvious 
difference in the prevalence of AEFI with 
respect to the sex of the children. This is 
different from the results obtained from 
studies conducted in Ilorin, Nigeria11 and 
Oman20 where male children experienced 
AEFI more than their female counterparts. 
This may be a chance occurrence since the 
study population of males was more than 
that of females in the studies. 
All the caregivers who had reported AEFI 
also stated that they received health 
educations on AEFI and its management 
from health workers in the clinic. This is 
commendable and indicates that health 
workers are familiar with AEFI identification 
and management. A study done in 
Alimosho, Lagos State, Nigeria revealed a 
similar finding.21 This would reinforce the 
knowledge of the caregivers about AEFI and 
alley possible fears that might occur as a 
result of side effects resulting from 
vaccination of children. Thus leading to 
improvement in routine immunization 
uptake. The major management measures 
mentioned at the immunization clinics 
during health education included: follow-up 
visits with the child to the hospital or see 
their doctor/nurses in cases of AEFI and 
use of simple interventions to reduce fever 
and pain from the AEFI. This implies that 
the content of health education is good and 
effective. 
Almost all the caregivers who had children 
with AEFI reported the occurrence at the 
immunization clinic and to a doctor or a 
nurse. A study done in the Netherlands 
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reported similar results.22 About a third of 
these caregivers were sure of the 
documentation of the reported AEFI. 
Documentation of AEFIs should be 
encouraged and sustained. Health workers 
should be trained and retrained on the 
importance of documenting AEFI since this 
will enhance surveillance in case of an 
outbreak. The supposed low documentation 
of AEFI reported by caregivers might be 
because health workers are aware that not 
all side effects reported from vaccination are 
AEFI that should be notified. Health 
education of mothers on possible side 
effects of vaccination should be done 
routinely.  
More than half of the caregivers reported 
adverse effects few hours after vaccination. 
This further emphasizes the good health-
seeking behaviour of the respondents. This 
will enable early detection and management 
of any life-threatening conditions associated 
with immunization. Only a small proportion 
of respondents’ children were hospitalized 
for signs of AEFI such as fever, skin 
reactions including swellings of vaccination 
sites and they fully recovered from the 
condition. This was similar to findings in a 
study conducted in Cotonou, Benin 
Republic.23 Hospitalization and mortality 
from reported AEFI are rare. This may be 
because majority of the AEFI observed were 
minor and not life threatening. This explains 
why several literatures are of the view that 
the benefits of immunizing a child far 
outweighs the risk and the chances of dying 
from vaccine-preventable diseases (VPDs) is 
higher than dying from the AEFI.4,24,25 The 
limitation of study included possible recall 
bias and self-reporting by the respondents 
which could not be verified by the 
researchers because of the study design 
utilized for the study. 
Conclusion: The prevalence of perceived 
AEFI was 42.3%. The AEFI occurred mainly 
after BCG and pentavalent vaccines 
administration. Almost all cases of 
perceived AEFI were reported promptly at 
the health facility. The caregivers exhibited 
good health-seeking behaviour with respect 
to the perceived AEFI occurrence which 
could be linked to valuable health education 
sessions attended in the health facilities.  
Documentation of reported AEFI should be 
improved on at the health facilities in order 
to detect surges of AEFI and ensure early 
diagnosis and prompt management of AEFI. 
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